<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085186</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17030033</org_study_id>
    <nct_id>NCT03085186</nct_id>
  </id_info>
  <brief_title>Treatment With Crizotinib Single Patient Expanded Access IND 134375</brief_title>
  <official_title>Treatment With Crizotinib Single Patient Expanded Access IND 134375</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean M. Tersak, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient&#xD;
      presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and&#xD;
      constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of&#xD;
      abdomen.&#xD;
&#xD;
      Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more&#xD;
      optimal tissue plains between vital structures prior to attempted surgical resection would&#xD;
      greatly reduce potential morbidity for this patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Inflammatory Myofibroblastic Tumour</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  This treatment plan is intended for the use of Crizotinib in the treatment of a single&#xD;
             patient with Inflammatory Myofibroblastic Tumour&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not applicable as Expanded Access only includes one patient&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>2 Years</maximum_age>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jean M. Tersak, M.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

